The China Securities Regulatory Commission has approved the IPO registration of LYGEND RESOURCE (02245) on the Shenzhen Stock Exchange.
On August 7, the China Securities Regulatory Commission issued a reply approving the Initial Public Offering (IPO) registration of Ningbo Liqin Resource Technology Co., Ltd.
On August 7, the China Securities Regulatory Commission issued a reply concerning the approval of Ningbo LYGEND RESOURCE Technology Co., Ltd.'s initial public offering of shares. It is reported that LYGEND RESOURCE (02245) intends to be listed on the main board of the Shenzhen Stock Exchange, with China International Capital Corporation as its sponsor, aiming to raise 4.04682 billion yuan.
The prospectus shows that LYGEND RESOURCE is a global leader in the nickel industry chain. During the reporting period, its main business includes upstream nickel resource procurement, nickel product trading, and the production and sales of nickel products. The company is deeply engaged in the nickel industry chain, starting from nickel product trading and continuously expanding downstream within the nickel industry to complete multiple links of the industry chain layout. Through process innovation, technological research and development, and localized cooperation, the company has achieved efficient utilization of local resources, driven industrial upgrades, and provided crucial metal resource guarantees for domestic downstream industries, thus realizing a win-win situation for cross-border industrial layouts.
Related Articles

HSBC HOLDINGS (00005) spent HKD 49.5541 million to repurchase 304,800 shares on August 21.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874): The injection of dextroamphetamine sulfate (1ml:2mg) has passed the consistency evaluation of generic drugs.

LONGCHEER (09611) invested 4.5007 million yuan on August 24 to repurchase 122,200 A-shares.
HSBC HOLDINGS (00005) spent HKD 49.5541 million to repurchase 304,800 shares on August 21.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874): The injection of dextroamphetamine sulfate (1ml:2mg) has passed the consistency evaluation of generic drugs.

LONGCHEER (09611) invested 4.5007 million yuan on August 24 to repurchase 122,200 A-shares.

RECOMMEND





